http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-5241354-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-355
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-07
filingDate 2000-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2b04b213aad3e6579dd301b2f10a8fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1adab27f56c174c534a9cecc58c0f35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e228455851a071cfb8430cb20cb3e34f
publicationDate 2003-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CO-5241354-A1
titleOfInvention HCV COMBINATION THERAPY
abstract Methods for treating patients who have susceptible viral infections, especially chronic hepatitis C infection are described by administering to said patient a therapeutically effective amount of a combination therapy of interferon-alpha and ribavirin for a period sufficient to improve hemolysis related to Ribavirin
priorityDate 1999-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID515951
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419507729
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID37542

Total number of triples: 38.